Peroral endoscopic pyloromyotomy is efficacious and safe for refractory gastroparesis: prospective trial with assessment of pyloric function.


Journal

Endoscopy
ISSN: 1438-8812
Titre abrégé: Endoscopy
Pays: Germany
ID NLM: 0215166

Informations de publication

Date de publication:
01 2019
Historique:
pubmed: 13 6 2018
medline: 30 8 2019
entrez: 13 6 2018
Statut: ppublish

Résumé

Gastroparesis is a functional disorder with a variety of symptoms that is characterized by delayed gastric emptying in the absence of mechanical obstruction. A recent series of retrospective studies has demonstrated that peroral endoscopic pyloromyotomy (G-POEM) is a promising endoscopic procedure for treating patients with refractory gastroparesis. The aim of this prospective study was to evaluate the feasibility, safety, and efficacy of G-POEM. 20 patients with refractory gastroparesis (10 diabetic and 10 nondiabetic) were prospectively included in the trial. Patients were treated by G-POEM after evaluation of pyloric function using an endoscopic functional luminal imaging probe. Clinical responses were evaluated using the Gastroparesis Cardinal Symptom Index (GCSI), and quality of life was assessed using the Patient Assessment of Upper Gastrointestinal Disorders - Quality of Life scale and the Gastrointestinal Quality of Life Index scores. Gastric emptying was measured using 4-hour scintigraphy before G-POEM and at 3 months. Feasibility of the procedure was 100 %. Compared with baseline values, G-POEM significantly improved symptoms (GCSI: 1.3 vs. 3.5; G-POEM was efficacious and safe for treating refractory gastroparesis, especially in patients with low pyloric distensibility.

Sections du résumé

BACKGROUND
Gastroparesis is a functional disorder with a variety of symptoms that is characterized by delayed gastric emptying in the absence of mechanical obstruction. A recent series of retrospective studies has demonstrated that peroral endoscopic pyloromyotomy (G-POEM) is a promising endoscopic procedure for treating patients with refractory gastroparesis. The aim of this prospective study was to evaluate the feasibility, safety, and efficacy of G-POEM.
METHODS
20 patients with refractory gastroparesis (10 diabetic and 10 nondiabetic) were prospectively included in the trial. Patients were treated by G-POEM after evaluation of pyloric function using an endoscopic functional luminal imaging probe. Clinical responses were evaluated using the Gastroparesis Cardinal Symptom Index (GCSI), and quality of life was assessed using the Patient Assessment of Upper Gastrointestinal Disorders - Quality of Life scale and the Gastrointestinal Quality of Life Index scores. Gastric emptying was measured using 4-hour scintigraphy before G-POEM and at 3 months.
RESULTS
Feasibility of the procedure was 100 %. Compared with baseline values, G-POEM significantly improved symptoms (GCSI: 1.3 vs. 3.5;
CONCLUSION
G-POEM was efficacious and safe for treating refractory gastroparesis, especially in patients with low pyloric distensibility.

Identifiants

pubmed: 29895073
doi: 10.1055/a-0628-6639
doi:

Banques de données

ClinicalTrials.gov
['NCT02779920']

Types de publication

Clinical Trial Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

40-49

Informations de copyright

© Georg Thieme Verlag KG Stuttgart · New York.

Déclaration de conflit d'intérêts

Jérémie Jacques is a cosnultant for Boston Scientific. Romain Legros is a consultant for Boston Scientific

Auteurs

Jérémie Jacques (J)

Service de Gastroentérologie, CHU Limoges, Limoges, France.
CNRS, XLIM, UMR 7252, Limoges, France.

Lauriane Pagnon (L)

Service de Gastroentérologie, CHU Limoges, Limoges, France.

Florent Hure (F)

Service de Biostatistiques, CHU Limoges, Limoges, France.

Romain Legros (R)

Service de Gastroentérologie, CHU Limoges, Limoges, France.

Sabrina Crepin (S)

Unité de Vigilance des Essais Cliniques, CHU Limoges, Limoges, France.

Anne-Laure Fauchais (AL)

Service de Médecine Interne, CHU Limoges, Limoges, France.

Sylvain Palat (S)

Service de Médecine Interne, CHU Limoges, Limoges, France.

Philippe Ducrotté (P)

Service de Gastroentérologie et Physiologie Digestive, CHU Charles Nicolle, Rouen, France.

Benoit Marin (B)

Service de Biostatistiques, CHU Limoges, Limoges, France.

Sebastien Fontaine (S)

Service de Diabétologie, CHU Toulouse, Toulouse, France.

Nour Edine Boubaddi (NE)

Service de Gastroentérologie, CH Brive-la-Gaillarde, Brive-la-Gaillarde, France.

Marie-Pierre Clement (MP)

Service de Diabétologie, CHU Limoges, Limoges, France.

Denis Sautereau (D)

Service de Gastroentérologie, CHU Limoges, Limoges, France.

Veronique Loustaud-Ratti (V)

Service de Gastroentérologie, CHU Limoges, Limoges, France.

Guillaume Gourcerol (G)

Service de Gastroentérologie et Physiologie Digestive, CHU Charles Nicolle, Rouen, France.

Jacques Monteil (J)

Service de Médecine Nucléaire, CHU Limoges, Limoges, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH